2F-DCK 50 MG Pellets Product Description

Introduction

2F-DCK, also known as 2-Fluorodeschloroketamine, is a synthetic dissociative anesthetic belonging to the arylcyclohexylamine class, structurally related to ketamine. It features the replacement of ketamine’s chlorine atom with a fluorine atom at the ortho (2-) position on the phenyl ring. Supplied as 50 mg pellets, 2F-DCK is designed for laboratory research to investigate its pharmacological and neurochemical properties. This compound is intended exclusively for scientific research use and not for human consumption or medical use.

Chemical Properties and Specifications

Structural and Molecular Characteristics

Physical Properties and Purity Standards

• Appearance: White to off-white solid pellets, each precisely containing 50 mg of 2F-DCK.

• Purity: Research-grade purity generally ≥ 97%, verified by chromatographic and spectroscopic analysis.

• Solubility: Soluble in polar organic solvents including dimethyl sulfoxide (DMSO), dimethylformamide (DMF), ethanol, and methanol; moderate solubility in aqueous phosphate-buffered saline (PBS).

• Storage Recommendations: Store pellets in airtight, light-resistant containers under cool, dry conditions, ideally refrigerated between 2°C and 8°C. Protect from moisture and direct sunlight to maintain compound stability for up to 2 years.

Pharmacological Profile and Mechanism of Action

Proposed Mechanism of Action

2F-DCK operates mainly by antagonizing the N-methyl-D-aspartate (NMDA) receptor, inhibiting excitatory glutamate neurotransmission in the brain. This results in dissociative anesthetic effects similar to ketamine, including sensory perceptual disruptions, cognitive detachment, and analgesia. The fluorine atom substituent alters its pharmacokinetic profile, potentially prolonging effects and modifying receptor affinity compared to ketamine. Functional assays suggest it retains comparable potency and efficacy to ketamine but with distinct metabolic properties.

Research Applications

This compound is used in neuropharmacology, anesthesiology research, and behavioral studies to investigate NMDA receptor antagonism and dissociative states. Its close structural similarity to ketamine makes it valuable in comparative studies on pharmacodynamics, toxicology, metabolism, and potential therapeutic applications. Additionally, 2F-DCK is a key subject in forensic research and drug screening methodologies.

Comparative Analysis with Related Compounds

Comparison to Ketamine and Other Analogues

2F-DCK shares structural similarity with ketamine but with a fluorine atom replacing chlorine, affecting binding affinity, metabolic stability, and duration of action. Compared with deschloroketamine (DCK), absence of halogen substitution differences may result in a different metabolic rate and potency. As an arylcyclohexylamine, it shows strong NMDA antagonism typical of this drug class with potential for longer-lasting dissociative effects relative to ketamine.

Advantages for Research

• High purity and stable pellet formulation enable precise dosing and controlled experimental conditions.

• Structural uniqueness among ketamine analogs offers insights into effects of halogen substitution on receptor interactions and metabolism.

• Facilitates pharmacokinetic and behavioral comparisons for novel anesthetic research chemicals.

Safety and Handling Guidelines

Laboratory Safety

Users must employ full personal protective equipment (PPE), including gloves, safety glasses, and lab coats. Handling should be conducted in well-ventilated fume hoods to prevent inhalation or dermal exposure. Strict adherence to safety protocols is essential given the potent pharmacology and limited clinical data.

Disposal and Environmental Considerations

Dispose of chemical waste in accordance with institutional and hazardous waste regulations. Precautions should prevent environmental release, applying containment and neutralization procedures.

Regulatory Status

2F-DCK is classified as a controlled research chemical in many jurisdictions. Legally restricted to scientific research and experimentation by licensed entities.

Frequently Asked Questions (FAQs)

1. What is the typical dose in 2F-DCK pellets?

• Each pellet contains 50 mg of active 2F-DCK compound.

2. How does 2F-DCK differ from ketamine structurally?

• It features a fluorine atom replacing the chlorine atom in ketamine’s structure.

3. What is the primary mechanism of action of 2F-DCK?

• NMDA receptor antagonism resulting in dissociative effects.

4. How soluble is 2F-DCK?

• Soluble in DMSO, DMF, ethanol, and methanol; moderate aqueous solubility.

5. Is 2F-DCK legal to buy and use?

• It is regulated and limited for research use only under licensing agreements.

Conclusion

2F-DCK 50 MG Pellets offer a pure, structurally distinct dissociative research chemical closely related to ketamine with NMDA antagonist activity. Their pellet formulation supports accurate pharmacological, behavioral, and toxicological research under controlled lab conditions and regulatory oversight.